Stock report · Delisted · Nasdaq
CARGO Therapeutics, Inc. Common Stock (CRGX)
4.47USD Delisted Final close · Aug 18, 2025
CRGX no longer trades. CARGO Therapeutics, Inc. Common Stock was delisted from the Nasdaq in August 2025.
All prices on this page are historical. The last trade was on August 18, 2025, at $4.47.
CRGX stock price history
Final trading statistics
- Final close
- $4.47
- Final trading day
- Aug 18, 2025
- Market cap at delisting
- $216.19M
- Shares outstanding
- 48.36M
- Final 52-week range
- $3.00 – $25.45
- Avg. volume (final 3 mo.)
- 1,687,048
- All-time high
- $32.23 · Mar 2024
- All-time low
- $3.39 · Jan 2025
- Return since IPO
- -70.2%
- Beta
- —
- Book value / share
- $5.11
- Price / book
- 0.87
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc. was a clinical-stage biotech company designing cell therapies for U.S. cancer patients with the aim of a cure. Its lead candidate, CRG-023, was a tri-specific CAR T therapy in phase 1 aimed at B-cell cancers.
It also had an allogeneic platform, a universal vector meant to limit immune rejection so CAR T-cell therapy could work longer. Known as Syncopation Life Sciences, Inc. until September 2022, the company was incorporated in 2019 and based in San Carlos, California.
It became a subsidiary of Concentra Biosciences, LLC as of August 18, 2025. Its common stock was delisted from the Nasdaq that month, with the last trade on August 18, 2025 at $4.47.
- Exchange (former)
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Carlos, CA
- Employees
- 167
- IPO date
- November 10, 2023
- Delisted
- August 18, 2025
- SEC CIK
- 1966494
CARGO Therapeutics, Inc. Common Stock financials before the delisting
The last 4 fiscal years CARGO Therapeutics, Inc. Common Stock reported as a public company, fiscal year ending December.
CRGX revenue and net income
CRGX earnings per share
CRGX annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2024 | $0.00 | −$167.5M | −$3.72 |
| FY2023 | $0.00 | −$98.1M | −$48.86 |
| FY2022 | $0.00 | −$41.0M | — |
| FY2021 | $0.00 | −$5.8M | — |
Net income is GAAP. EPS is adjusted (non-GAAP) EPS, as reported.
CARGO Therapeutics, Inc. Common Stock stock FAQ
What happened to CARGO Therapeutics, Inc. Common Stock stock?
CARGO Therapeutics, Inc. Common Stock was delisted from the Nasdaq in August 2025. The final close was $4.47 on August 18, 2025.
Can I still buy CRGX stock?
No. CRGX is no longer listed on the Nasdaq or any other U.S. exchange; it was removed on August 18, 2025.
What was the last price of CRGX?
CRGX last closed at $4.47 on August 18, 2025, which valued the company at about $216.19M.
How did CARGO Therapeutics, Inc. Common Stock do in its last full fiscal year?
In fiscal 2024, its last full year as a public company, CARGO Therapeutics, Inc. Common Stock reported revenue of $0.00 and net income of −$167.5M.
When did CARGO Therapeutics, Inc. Common Stock go public?
CARGO Therapeutics, Inc. Common Stock shares started trading on November 10, 2023.
CRGX no longer trades, so there is no live quote. The information on this page is for reference only and is not investment advice; see our disclaimer.